查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1835323

婴儿痉挛症药物市场（依治疗层级、通路和给药途径）－全球预测 2025-2032

Infantile Spasms Therapeutics Market by Therapeutic Class, Distribution Channel, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，婴儿痉挛治疗市场将成长至 6.7912 亿美元，复合年增长率为 6.64%。

主要市场统计数据
基准年2024年 4.0601亿美元
预计2025年 4.3278亿美元
预测年份：2032年 6.7912亿美元
复合年增长率（%） 6.64%

简明的临床概况，重点在于重症加护挑战、诊断进展以及影响婴儿痉挛治疗的策略重点

儿童痉挛是一项极具挑战性的临床难题，其特征是早发性癫痫，病因复杂，且核准的治疗方案有限。临床医生、付款人和看护者所处的环境虽小，但最终风险巨大，快速诊断和有效治疗的启动可能会改变儿童的神经发育轨迹。临床重点——控制癫痫发作、最大程度减少治疗相关副作用以及保留神经发育潜能——促使人们同时大力推进既有方案和新型治疗方法。

在临床实践中，诊断技术的进步以及儿科神经科和新生儿科医生意识的提高，缩短了许多机构的治疗时间，但医疗服务可近性仍然参差不齐。这种差异源于转诊途径的差异、住院和门诊病人管理能力的差异，以及地理位置分散的地区某些专科治疗的可近性有限。因此，卫生系统和产业相关人员都必须协调临床需求与实际运作情况，以确保及时提供医疗服务。

同时，监管和报销方面的考量既带来了摩擦，也带来了机会。在罕见疾病治疗途径、神经发育结局证据标准不断演变以及高成本疗法的支付方审查交织的背景下，申办方和卫生系统领导者必须设计证据包，以证明除控制癫痫发作之外的显着临床效用。因此，整合临床试验设计、真实世界证据产生和相关人员参与的策略方法，对于推动能够实际改善儿童及其家庭结果的干预措施至关重要。

精准诊断、新治疗方法和新护理方法如何重新定义治疗模式和相关人员的期望

在诊断精准度不断提升、治疗方案日益丰富以及医疗服务模式不断发展的推动下，儿童癫痫治疗领域正在发生重大变化。基因和代谢检测的进步正在加速病因分类，使临床医生能够更精准地干预潜在的疾病机制，并制定个人化的治疗方案。因此，临床路径正在从「一刀切」的治疗方案转变为分层治疗方案，当确定特定的遗传或结构性病因时，优先考虑标靶治疗。

同时，治疗方法创新正在超越既定方案的渐进式改善。新型製剂、再利用化合物和生物製剂策略正进入开发平臺，重点在于提高耐受性和维持研发成果。这些科学进步正在重塑相关人员的期望，并鼓励监管机构对将癫痫发作指标与研发评估相结合的综合终点持开放态度。

医疗保健服务也在发生变化，数位医疗工具和远距神经病学加强了转诊网路和后续护理，改善了医疗服务匮乏地区的医疗可近性。支付者和医疗服务提供者越来越要求提供长期功能益处的证据，这促使製造商投资于纵向研究和真实世界证据平台。这些转变共同创造了一个更细緻入微、以患者为中心的生态系统，对癫痫发作和神经发育轨迹都产生了显着的影响。

检验进口关税和贸易政策的变化如何改变儿科神经病学的药品供应链、定价动态和病患获取途径

关税结构的政策变化可能会波及整个儿科痉挛供应链，影响製造决策、筹资策略以及专科治疗的可近性。对原料药和成品提高进口关税，可能会增加依赖跨境供应链的疗法的到岸成本，进而影响配方谈判、库存管理实践以及专科产品的地理分布。进口成本的上升可能会促使製造商考虑一些方案，例如将某些製造流程转移到国内、协商长期供应商协议或重新设计包装和分销方式，以降低单位物流成本。

此外，关税也可能与监管和报销框架相互影响。为了应对成本压力，付款方可能会收紧资格标准，采用阶梯式治疗方案，或要求更强有力的卫生经济学证据来证明获得高成本疗法的合理性。这些动态可能会影响上市时机和病患可及性计画的结构，尤其是在医院环境中进行或需要低温运输物流的疗法。为此，公司通常会加快与付款方和医疗系统的合作，以设计可及性途径，从而减轻定价的影响，同时保持患者护理的连续性。

最后，关税可能会促使人们更加重视区域製造地和战略库存配置。相关人员可以寻求风险共担协议、区域製造外包伙伴关係和策略储备，以保持供应的连续性。透过主动模拟关税情景，并使供应链反应与临床可及性优先顺序保持一致，製造商和卫生系统可以降低波动性，并确保癫痫婴儿和儿童获得治疗。

将治疗层级、分销管道和给药途径与临床采用模式和获取动态联繫起来的深刻細項分析

了解治疗细分有助于明确儿科痉挛领域的临床需求和发展重点。治疗层级框架区分了抗癫痫药物 (AED)（包括Vigabatrin等标靶药物）和荷尔蒙疗法荷尔蒙疗法（包括促肾上腺皮质激素和物流） 。这种区分对于理解临床应用、安全监测要求和分销物流的差异至关重要。每种治疗类别都有不同的处方模式和监测要求，这反过来又会影响临床医生培训、住院护理通讯协定和门诊病人追踪常规。

分销通路细分凸显了多样化的获取途径，这对于营运规划至关重要。医院药房是启动和监测住院患者复杂用药方案的主要管道，零售药房则支持持续的门诊配药和社区获取，而在线药房在专科药物履约和送货上门模式中发挥着越来越重要的作用。由于这些管道在报销机制、患者咨询能力以及支援低温运输和受控分销产品的能力方面存在差异，因此商业策略必须将通路选择与特定疗法的处理和管理需求相结合。

给药途径进一步影响了临床和商业方法。注射剂型需要肌肉注射或静脉注射，通常需要机构护理和训练有素的临床医生，而溶液或片剂形式的口服剂型更容易在门诊启动并由看护者管理。给药途径影响依从性考量、看护者教育要求和患者援助计划的设计，并影响製造商如何优先考虑配方创新以提高耐受性和易用性。认识到治疗层级、分销管道和给药途径之间的相互关係，有助于相关人员根据临床实际情况调整开发、上市和服务交付策略。

美洲、欧洲、中东和非洲以及亚太地区的临床、监管和商业性动态影响着药物的取得和策略重点

区域动态影响全球儿科痉挛治疗系统的临床实务、监管预期和商业性重点。在美洲，集中式学术中心和一体化医疗体系往往推动着先进诊断和专科疗法的早期采用，而支付方结构和区域处方集则影响可及性途径和签约策略。因此，该地区的相关人员可能会优先考虑产生可靠的真实世界证据和支付方参与，以确保及时获得治疗并支持报销决策。

欧洲、中东和非洲地区医疗保健系统的差异性导致诊断能力和资源配置存在差异。有些市场迅速采用基因检测和生物製药，而有些市场则依赖更传统的医院式医疗模式。这种差异需要采取差异化的市场策略，结合能力建构措施和本地临床教育，尽可能实现医疗标准化。此外，欧洲的监管协调和中东地区新的报销框架可能为协调一致的产品发布创造机会。

亚太地区市场多元化，人口众多，专业医疗基础设施快速扩张，监管环境和本地製造能力也各不同。在一些国家，公共卫生重点和不断发展的新生儿护理计画已改善了早期发现和转诊。在所有地区，将证据产生、分发策略和相关人员参与与当地临床实践和政策环境相结合，对于支持癫痫发作婴儿获得治疗并改善其预后仍然至关重要。

企业策略模式揭示了治疗方法开发、伙伴关係和获取计划如何与临床差异化和现实世界交付挑战一致

在儿科痉挛领域营运的主要企业正在推行各种策略重点，共同推动治疗方案和患者支持基础设施的改进。一些公司专注于优化配方和改进给药途径，以提高耐受性并实现门诊病人管理；而另一些公司则投资于伴随诊断和基因检测合作，以更好地定义患者亚群并支持精准医疗路径。这些倡议体现了对临床差异化和实际效用的双重关注。

伙伴关係与联盟活动也十分活跃，商业性和学术合作加速了转化研究和核准后证据的生成。认识到纵向数据对临床医生和付款人的重要性，各公司正在越来越多地整合药物安全检测和患者支持服务，以增强依从性并监测长期开发成果。此外，一些公司正在探索製造伙伴关係和本地供应策略，以提高低温运输的市场的可得性。

从商业性角度来看，各公司正在完善可及性方案，更早与付款人接触，并设计基于结果的合约模式，以实现价值与成本的平衡。这些战术性方法体现了这样一种理念：临床疗效必须与可证实的功能益处和可行的交付模式相结合，才能实现更广泛的应用。整体而言，该领域的企业策略在科学创新与实际努力之间取得平衡，以确保治疗惠及有需要的婴幼儿。

为公司提供实用且具战略意义的建议，将诊断、付款人参与、供应弹性和证据生成纳入综合商业计划

透过协调临床开发、可近性策略和营运能力，产业领导者可以采取果断措施，改善患者治疗效果并提升商业性绩效。首先，公司应将病因诊断策略整合到开发项目和商业计划中，并确保临床试验和真实世界证据收集能够反映儿童痉挛患者的异质性。此外，投资配方创新和看护者为中心的给药解决方案，可以减少门诊管理的障碍，并提高病患依从性。

其次，积极主动地与付款方沟通并采用灵活的合约方式可以缓解患者就医的阻力。透过及早与付款方沟通，就有意义的临床和研发终点达成一致，并探索基于结果或风险共担的协议，公司可以在维护患者可及性的同时，向医疗保健系统展示其价值。同时，建立强大的患者支援服务和教育资源，可以帮助家庭和临床医生应对复杂的治疗途径和监测要求。

第三，应优先考虑供应链韧性，透过策略製造伙伴关係、区域库存策略以及针对贸易政策影响的情境规划来实现。企业还应建立纵向证据平台和註册中心，以收集长期的开发成果和安全资料。透过协调临床、商业性和营运倡议，行业领导者可以实现可衡量的医疗改善，并建立永续的创新治疗方法获取途径。

一种强大而透明的调查方法，结合专家访谈、临床文献综述、监管和专利分析以及数据三角测量来检验见解

本分析所采用的调查方法将结构化的一手资料研究与广泛的二手资料整合以及严格的三角检定相结合，以确保信度和效度。一手资料研究包括对儿科神经科、医院药剂师、卫生系统负责人和付款人代表的深入访谈，以了解临床实践模式、处方决定因素和运作限制。这些工作为不同医疗机构的诊断工作流程、治疗启动决策和后续照护模式提供了定性见解。

二次研究包括对同行评审临床文献、临床试验註册库、监管部门核准和产品说明书进行系统性回顾，以绘製治疗机制、安全性和核准核准图谱。我们也探讨了专利格局和上市公司资讯揭露，以了解研发轨迹、生产足迹和伙伴关係活动。我们还分析了来自临床註册库和真实世界证据来源的数据，以将纵向结果与背景联繫起来，并识别与付款人和指南委员会相关的证据缺口。

资料合成包括对定性输入和次要发现进行三角检验，以检验新兴主题并突出共识和争议领域。在可能的情况下，定量资料集会与多个独立资讯来源进行交叉核对，以确保一致性。在整个过程中，我们采用了访谈指南、受访者检验和迭代假设检验等方法学保障措施，以减少偏差并提高结论的可靠性。

简洁的综合强调如何整合临床创新、运作执行和证据策略来改善治疗机会和发展结果

摘要：儿童癫痫治疗领域正处于曲折点，精准诊断、治疗创新和不断发展的护理模式正在融合，为改善临床疗效创造有意义的机会。相关人员面临着证明功能性益处和实用化治疗方法被广泛采用的双重挑战，因此需要製定涵盖临床开发、证据生成、付款人参与和供应链设计的协作策略。透过将临床终点与神经发育结果相结合，并投资于纵向资料收集，申办者可以强化新型和再利用疗法的价值提案。

在营运方面，由于地区基础设施和分销管道动态的差异，需要采取量身定制的方案来应对当地的诊断能力、住院转诊的过渡路径以及物流问题。重视配方改进、看护者支援和本地供应弹性的公司将更有能力实现持续的临床应用。最终，成功取决于一种能够平衡科学创新与实际执行的综合观点，为受癫痫影响的婴儿和儿童开闢一条及时获得有效治疗方法并改善生命历程结局的道路。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 婴儿痉挛症治疗中基因生物标记指导治疗策略的进展
  • 安全性较高的合成促肾上腺皮质激素类似物在治疗婴儿痉挛症的出现
  • 扩大新兴市场婴儿痉挛症患者的治疗管道和早期诊断
  • 加速监管部门核准用于治疗IS的神经发炎调节剂
  • 整合远端医疗监测和基于人工智慧的癫痫发作检测，用于婴儿痉挛管理
  • 以大麻二酚为基础的难治性婴儿痉挛症辅助性治疗临床试验取得突破
  • 生技公司与学术机构结成策略联盟，精准治疗婴儿痉挛症

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 婴儿痉挛症药物市场（依治疗层级）

  • 抗癫痫药物
    • Vigabatrin
  • 荷尔蒙疗法
    • 促肾上腺皮质激素
    • 皮质类固醇

9. 婴儿痉挛药物市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第十章婴儿痉挛药物市场（依给药途径）

  • 注射
    • 肌肉注射
    • 静脉
  • 口服
    • 解决方案
    • 药片

第 11 章：婴儿痉挛药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第12章婴儿痉挛药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章婴儿痉挛药物市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Mallinckrodt plc
    • UCB Pharma SA
    • Teva Pharmaceutical Industries Ltd.
    • BIOSPACE, INC.
    • ORPHELIA Pharma
    • Amneal Pharmaceuticals LLC
    • CIPLA LIMITED
    • Zydus Group
    • Marinus Pharmaceuticals, Inc.
    • Ovid Therapeutics, Inc.
Product Code: MRR-43127F727967

The Infantile Spasms Therapeutics Market is projected to grow by USD 679.12 million at a CAGR of 6.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 406.01 million
Estimated Year [2025] USD 432.78 million
Forecast Year [2032] USD 679.12 million
CAGR (%) 6.64%

A concise clinical landscape overview that articulates the critical care challenges, diagnostic progress, and strategic imperatives shaping infantile spasms therapeutics

Infantile spasms present a uniquely urgent clinical challenge characterized by an early-life seizure disorder with complex etiologies and a constrained set of approved therapeutic options. Clinicians, payers, and caregivers operate within a high-stakes environment where rapid diagnosis and initiation of effective therapy can reshape neurodevelopmental trajectories, making the therapeutic landscape small in scale but large in consequence. The clinical priorities center on seizure control, minimization of treatment-related adverse effects, and preservation of neurodevelopmental potential, which together drive intense focus on both established regimens and emerging interventions.

Across clinical practice, diagnostic advances and heightened awareness among pediatric neurologists and neonatologists have shortened time-to-treatment in many centers, but variability in access persists. This variation stems from differences in referral pathways, inpatient versus outpatient management capacity, and constrained availability of certain specialty therapies in geographically dispersed settings. Consequently, health systems and industry stakeholders alike must reconcile clinical imperatives with operational realities to ensure timely delivery of care.

In parallel, regulatory and reimbursement considerations create both friction and opportunity. The intersection of orphan disease pathways, evolving evidence standards for neurodevelopmental outcomes, and payer scrutiny of high-cost therapies requires sponsors and health system leaders to design evidence packages that demonstrate meaningful clinical benefit beyond seizure control. Therefore, a strategic approach that integrates clinical trial design, real-world evidence generation, and stakeholder engagement is essential to advance interventions that meaningfully improve outcomes for affected infants and their families.

How precision diagnostics, emerging therapeutic modalities, and new care delivery approaches are together redefining treatment paradigms and stakeholder expectations

The infantile spasms treatment landscape is undergoing transformative shifts driven by innovations in precision diagnostics, expanded therapeutic modalities, and evolving care delivery models. Advances in genetic and metabolic testing have accelerated etiologic classification, enabling clinicians to match interventions more closely to underlying disease mechanisms and thereby personalizing treatment choices. As a result, clinical pathways are adapting from one-size-fits-all algorithms toward stratified approaches that prioritize targeted therapies when a specific genetic or structural cause is identified.

Concurrently, therapeutic innovation extends beyond incremental improvements to established regimens. Novel formulations, repurposed compounds, and biologic strategies are entering development pipelines with an emphasis on improved tolerability and sustained developmental outcomes. These scientific advances are reshaping stakeholder expectations and prompting regulators to signal openness to integrated endpoints that combine seizure metrics with developmental assessments.

Care delivery has also shifted, with digital health tools and tele-neurology augmenting referral networks and follow-up care, thus improving access in underserved regions. Payers and providers increasingly seek evidence of longer-term functional benefit, which encourages manufacturers to invest in longitudinal studies and real-world evidence platforms. Taken together, these shifts are converging to create a more nuanced, patient-centered ecosystem that rewards demonstrable impact on both seizures and neurodevelopmental trajectories.

An examination of how changes in import duties and trade policy can alter pharmaceutical supply chains, pricing dynamics, and patient access pathways in pediatric neurology

Policy shifts in tariff structures can ripple across the infantile spasms supply chain with implications for manufacturing decisions, procurement strategies, and access to specialty therapeutics. Increased import duties on active pharmaceutical ingredients or finished drug products tend to raise landed costs for therapies that rely on cross-border supply chains, which can in turn influence formulary negotiations, inventory management practices, and the geographic distribution of specialty products. When import costs rise, manufacturers may evaluate options such as onshoring certain production steps, negotiating long-term supplier contracts, or redesigning packaging and distribution to reduce per-unit logistics expenses.

Moreover, tariffs can interact with regulatory and reimbursement frameworks. Payers responding to cost pressures may tighten coverage criteria, adopt step therapy practices, or insist on more robust health economic evidence to justify access to high-cost treatments. These dynamics can affect the timing of commercial launches and the structure of patient access programs, particularly for therapies administered in hospital settings or those requiring cold-chain logistics. In response, companies often accelerate engagement with payers and health systems to design access pathways that mitigate pricing impacts while maintaining continuity of care for patients.

Lastly, tariffs can prompt greater emphasis on regional manufacturing hubs and strategic inventory positioning. Stakeholders may pursue risk-sharing agreements, localized contract manufacturing partnerships, or strategic stockpiling to preserve supply continuity. By proactively modeling tariff scenarios and aligning supply chain responses with clinical access priorities, manufacturers and health systems can reduce volatility and safeguard treatment availability for infants with spasms.

Insightful segmentation analysis that links therapeutic classes, distribution channels, and routes of administration to clinical adoption patterns and access dynamics

Understanding therapeutic segmentation clarifies where clinical demand and development energy concentrate within the infantile spasms arena. The therapeutic class framework separates anti-epileptic drugs from hormonal therapies, with the anti-epileptic segment exemplified by targeted agents such as vigabatrin, while hormonal approaches encompass adrenocorticotropic hormone and corticosteroids; this classification is critical to appreciating differences in clinical adoption, safety monitoring needs, and distribution logistics. Each therapeutic class carries distinct prescribing patterns and monitoring requirements, which in turn shape clinician training, inpatient care protocols, and outpatient follow-up routines.

Distribution channel segmentation highlights divergent access pathways that matter for operational planning. Hospital pharmacies serve as principal channels for inpatient initiation and monitoring of complex regimens, while retail pharmacies support ongoing outpatient dispensing and community access, and online pharmacies play an increasing role in specialty medication fulfillment and home delivery models. These channels differ in their reimbursement mechanisms, patient counseling capabilities, and ability to support cold-chain or controlled distribution products, so commercial strategies must align channel choice with therapy-specific handling and administration needs.

Route of administration further nuances clinical and commercial approaches, with injectable preparations requiring intramuscular or intravenous administration that often necessitates facility-based care and trained clinicians, whereas oral formulations in solution or tablet form facilitate outpatient initiation and caregiver-managed dosing. The administration route affects adherence considerations, caregiver education requirements, and the design of patient support programs, and it influences how manufacturers prioritize formulation innovation to improve tolerability and ease of use. Recognizing how therapeutic class, distribution channel, and route of administration intersect enables stakeholders to tailor development, market access, and service delivery strategies to the realities of clinical practice.

Regional clinical, regulatory, and commercial dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence access and strategic priorities

Regional dynamics shape clinical practice, regulatory expectations, and commercial prioritization across global infantile spasms care delivery systems. In the Americas, concentrated academic centers and integrated health systems often drive early adoption of advanced diagnostics and specialty therapies, while payer structures and regional formularies influence access pathways and contracting strategies. Consequently, stakeholders in this region may prioritize robust real-world evidence generation and payer engagement to secure timely access and to support reimbursement decisions.

Within Europe, Middle East & Africa, heterogeneity across health systems yields variable diagnostic capacity and resource allocation, with some markets demonstrating rapid uptake of genetic testing and biologic therapies, whereas others remain reliant on more traditional inpatient-based treatment models. This variation necessitates differentiated market approaches that incorporate capacity-building initiatives and local clinical education to standardize care where possible. Additionally, regulatory harmonization efforts in Europe and emerging reimbursement frameworks in the Middle East can create opportunities for aligned product launches.

Asia-Pacific presents a diverse landscape where populous markets combine rapidly expanding specialty care infrastructure with variable regulatory pathways and local manufacturing capabilities. In several countries, public health priorities and evolving neonatal care programs have led to improved early detection and referral, while manufacturers may leverage regional production hubs and partnership models to enhance supply chain resilience. Across all regions, tailoring evidence generation, distribution strategies, and stakeholder engagement to regional clinical practices and policy environments remains essential to supporting access and improving outcomes for infants affected by spasms.

Corporate strategy patterns revealing how therapy development, partnerships, and access programs are aligned to clinical differentiation and practical delivery challenges

Leading companies operating in the infantile spasms domain are pursuing an array of strategic priorities that collectively advance therapeutic options and patient support infrastructure. Several firms have concentrated on formulation optimization and route-of-administration improvements to enhance tolerability and enable outpatient management, while others have invested in companion diagnostics and genetic testing collaborations to better define patient subgroups and support precision care pathways. These moves demonstrate a dual focus on clinical differentiation and practical usability in real-world settings.

Partnership and alliance activity is also prominent, with commercial and academic collaborations accelerating translational research and post-approval evidence generation. Firms are increasingly integrating pharmacovigilance and patient support services to strengthen adherence and to monitor long-term developmental outcomes, acknowledging the importance of longitudinal data for clinicians and payers alike. In addition, some companies are exploring manufacturing partnerships and regional supply strategies to improve availability in markets with constrained cold-chain or specialty pharmacy infrastructures.

From a commercial standpoint, organizations are refining access programs, engaging payers early, and designing outcomes-based contracting models to align value with cost. These tactical approaches reflect an understanding that clinical efficacy must be paired with demonstrable functional benefit and feasible delivery models to achieve broader adoption. Overall, corporate strategies in this space balance scientific innovation with pragmatic efforts to ensure therapies reach infants in need.

Practical and strategic recommendations for companies to integrate diagnostics, payer engagement, supply resilience, and evidence generation into cohesive commercial plans

Industry leaders can take decisive steps to improve patient outcomes and commercial performance by aligning clinical development, access strategies, and operational capabilities. First, companies should integrate etiologic diagnostic strategies into development programs and commercial planning so that trials and real-world evidence collection reflect the heterogeneity of the infantile spasms population; doing so enhances the relevance of trial endpoints and supports targeted labeling and reimbursement dialogues. In addition, investing in formulation innovation and caregiver-centric delivery solutions will reduce barriers to outpatient management and improve adherence.

Second, proactive payer engagement and flexible contracting approaches can mitigate access friction. Engaging payers early to agree on meaningful clinical and developmental endpoints, and exploring outcomes-based or risk-sharing agreements, can help companies demonstrate value to health systems while preserving patient access. Concurrently, establishing robust patient support services and education resources will assist families and clinicians in navigating complex treatment pathways and monitoring requirements.

Third, supply chain resilience should be prioritized through strategic manufacturing partnerships, regional inventory strategies, and scenario planning for trade policy impacts. Companies should also build longitudinal evidence platforms and registries to capture developmental outcomes and safety data over time, since these data support adoption, inform guideline updates, and strengthen payer negotiations. By coordinating clinical, commercial, and operational initiatives, industry leaders can deliver measurable improvements in care and create sustainable paths to access for innovative therapies.

A robust and transparent research methodology combining expert interviews, clinical literature review, regulatory and patent analysis, and data triangulation to validate insights

The research methodology underpinning this analysis combined structured primary research with extensive secondary source synthesis and rigorous triangulation to ensure credibility and relevance. Primary research included in-depth interviews with pediatric neurologists, hospital pharmacists, health system leaders, and payer representatives to capture clinical practice patterns, formulary decision drivers, and operational constraints. These engagements provided qualitative insights into diagnostic workflows, treatment initiation decisions, and follow-up care models across diverse care settings.

Secondary research encompassed a systematic review of peer-reviewed clinical literature, clinical trial registries, regulatory approvals, and product labeling to map therapeutic mechanisms, safety profiles, and approved indications. Patent landscapes and public company disclosures were examined to understand development trajectories, manufacturing footprints, and partnership activities. Data from clinical registries and real-world evidence sources were analyzed to contextualize longitudinal outcomes and to identify evidence gaps relevant to payers and guideline committees.

Data synthesis involved triangulating qualitative input and secondary findings to validate emergent themes and to highlight areas of consensus and controversy. Where possible, quantitative datasets were cross-checked against multiple independent sources to ensure consistency. Throughout, methodological safeguards such as interviewer guides, respondent validation, and iterative hypothesis testing were employed to reduce bias and to enhance the reliability of the conclusions presented.

A concise synthesis highlighting how integrated clinical innovation, operational execution, and evidence strategies can improve therapeutic access and developmental outcomes

In summary, the infantile spasms therapeutics landscape stands at an inflection point where precision diagnostics, therapeutic innovation, and evolving care models converge to create meaningful opportunities for improved clinical outcomes. Stakeholders face the twin imperatives of demonstrating functional benefit and ensuring practical delivery of therapies, which requires coordinated strategies spanning clinical development, evidence generation, payer engagement, and supply chain design. By aligning clinical endpoints with neurodevelopmental outcomes and by investing in longitudinal data capture, sponsors can strengthen the value proposition of novel and repurposed therapies alike.

Operationally, differences in regional infrastructure and distribution channel dynamics necessitate tailored approaches that address local diagnostic capacity, inpatient-to-outpatient transition pathways, and logistics. Companies that prioritize formulation improvements, caregiver support, and regional supply resilience will be better positioned to achieve sustained clinical uptake. Ultimately, success will depend on an integrated view that balances scientific innovation with pragmatic execution, thereby creating pathways for timely access to effective therapies and improved life-course outcomes for infants affected by spasms.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in genetic biomarker-guided therapeutic strategies for infantile spasms management
  • 5.2. Emergence of synthetic ACTH analogues with enhanced safety profiles in infantile spasms treatment
  • 5.3. Expansion of patient access and early diagnosis initiatives in emerging markets for infantile spasms
  • 5.4. Regulatory fast-track approvals for repurposed neuroinflammatory modulators in IS treatment
  • 5.5. Integration of telehealth monitoring and AI-enabled seizure detection for infantile spasms management
  • 5.6. Clinical trial breakthroughs in cannabidiol-based adjunct therapies for refractory infantile spasms
  • 5.7. Strategic partnerships between biotech firms and academic centers for precision infantile spasms medicine

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infantile Spasms Therapeutics Market, by Therapeutic Class

  • 8.1. Anti-Epileptic Drugs
    • 8.1.1. Vigabatrin
  • 8.2. Hormonal Therapies
    • 8.2.1. Adrenocorticotropic Hormone
    • 8.2.2. Corticosteroids

9. Infantile Spasms Therapeutics Market, by Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies

10. Infantile Spasms Therapeutics Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Intravenous
  • 10.2. Oral
    • 10.2.1. Solution
    • 10.2.2. Tablet

11. Infantile Spasms Therapeutics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Infantile Spasms Therapeutics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Infantile Spasms Therapeutics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Mallinckrodt plc
    • 14.3.2. UCB Pharma SA
    • 14.3.3. Teva Pharmaceutical Industries Ltd.
    • 14.3.4. BIOSPACE, INC.
    • 14.3.5. ORPHELIA Pharma
    • 14.3.6. Amneal Pharmaceuticals LLC
    • 14.3.7. CIPLA LIMITED
    • 14.3.8. Zydus Group
    • 14.3.9. Marinus Pharmaceuticals, Inc.
    • 14.3.10. Ovid Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. INFANTILE SPASMS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. INFANTILE SPASMS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INFANTILE SPASMS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 240. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 251. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 256. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 257. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 258. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 259. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 264. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 265. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 266. GCC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 299. G7 INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024